Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00378-2512-78 00378-2512 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Aug 8, 2014 Jun 30, 2023 No Longer Used
51407-0909-01 51407-0909 HYDROXYUREA HYDROXYUREA 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Apr 22, 2024 In Use
68001-0488-07 68001-0488 CAPECITABINE CAPECITABINE 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb 22, 2021 In Use
65162-0844-50 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 10, 2017 Feb 1, 2024 No Longer Used
70518-0916-01 70518-0916 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Dec 18, 2019 In Use
68462-0882-60 68462-0882 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 19, 2022 In Use
69238-1754-06 69238-1754 ABIRATERONE ABIRATERONE ACETATE 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Jan 7, 2019 In Use
43598-0468-38 43598-0468 Abiraterone Acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Sep 11, 2023 In Use
54868-4773-00 54868-4773 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Apr 11, 2003 In Use
69539-0319-05 69539-0319 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Apr 26, 2024 In Use
69539-0020-92 69539-0020 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jul 2, 2018 In Use
57894-0199-06 57894-0199 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Mar 5, 2018 Sep 2, 2021 In Use
43598-0468-60 43598-0468 Abiraterone Acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Sep 11, 2023 In Use
63629-9430-01 63629-9430 Abiraterone acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Aug 23, 2022 In Use
31722-0775-12 31722-0775 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 5, 2024 In Use
00555-0882-02 00555-0882 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Oct 19, 1998 In Use
54868-4773-01 54868-4773 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Apr 11, 2003 In Use
00004-1101-51 00004-1101 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 5, 2010 Dec 20, 2011 No Longer Used
60429-0265-01 60429-0265 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Oct 26, 2012 Dec 31, 2024 No Longer Used
69025-0131-01 69025-0131 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Apr 11, 2023 In Use
54868-4773-02 54868-4773 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Apr 11, 2003 In Use
54868-5260-02 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
00003-0830-50 00003-0830 Hydroxyurea Hydrea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Jun 1, 2009 Mar 31, 2025 No Longer Used
54868-5260-05 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
00015-3080-60 00015-3080 Mitotane Lysodren 500.0 mg/1 Chemotherapy Miscellaneous Agent Adrenal Suppressant Oral Jun 1, 2009 Mar 31, 2021 No Longer Used

Found 12159 results — Export these results